Risk factors

Immix Biopharma (IMMX) risk factors

Item 1A of every Immix Biopharma, Inc. 10-K on file, and what changed from one year to the next.

Open IMMX in Gloomberb →
  • FY2025 10-K risk factors

    56 risks, 5 new, 1 dropped, 4 reworded since the prior year. Cash and cash equivalents grew to $100.4 million as of December 31, 2025, up from $17.7 million.

    Filed Mar 25, 2026
  • FY2024 10-K risk factors

    52 risks. Immix Biopharma faces substantial capital requirements, relying heavily on existing cash of $17.7 million and external grants. The company carries zero product revenues and depends entirely on unproven clinical candidates. Intellectual property defense and regulatory compliance dictate operational viability.

    Filed Mar 25, 2025